Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin J Kim

Showing results (51-60 of 55) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 55 results.
Scientific Reports|July 2, 2025
Choroidal evaluation of FTLD-Tau and biomarker-determined Alzheimer's diseaseBenjamin J Kim, Tomas S Aleman, Katheryn A Q Cousins, et al.
Neurobiology of Aging|March 1, 2023
Retinal photoreceptor layer thickness has disease specificity and distinguishes predicted FTLD-Tau from biomarker-determined Alzheimer's diseaseBenjamin J Kim, Murray Grossman, Tomas S Aleman, et al.
Retina (Philadelphia, Pa.)|January 12, 2018
FREQUENT SUBCLINICAL MACULAR CHANGES IN COMBINED BRAF/MEK INHIBITION WITH HIGH-DOSE HYDROXYCHLOROQUINE AS TREATMENT FOR ADVANCED METASTATIC BRAF MUTANT MELANOMA: Preliminary Results From a Phase I/II Clinical Treatment TrialAkosua A Nti, Leona W Serrano, Harpal S Sandhu, et al.
Clinical Immunology (Orlando, Fla.)|April 2, 2020
Prolonged intraocular residence and retinal tissue distribution of a fourth-generation compstatin-based C3 inhibitor in non-human primatesSarah Hughes, Justin Gumas, Rebecca Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2022
BAMM (BRAF Autophagy and MEK Inhibition in Melanoma): A Phase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine in Advanced BRAFV600-mutant MelanomaJanice M Mehnert, Tara C Mitchell, Alexander C Huang, et al.
Pageof 6

Showing results (51-60 of 55) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 55 results.
Scientific Reports|July 2, 2025
Choroidal evaluation of FTLD-Tau and biomarker-determined Alzheimer's diseaseBenjamin J Kim, Tomas S Aleman, Katheryn A Q Cousins, et al.
Neurobiology of Aging|March 1, 2023
Retinal photoreceptor layer thickness has disease specificity and distinguishes predicted FTLD-Tau from biomarker-determined Alzheimer's diseaseBenjamin J Kim, Murray Grossman, Tomas S Aleman, et al.
Retina (Philadelphia, Pa.)|January 12, 2018
FREQUENT SUBCLINICAL MACULAR CHANGES IN COMBINED BRAF/MEK INHIBITION WITH HIGH-DOSE HYDROXYCHLOROQUINE AS TREATMENT FOR ADVANCED METASTATIC BRAF MUTANT MELANOMA: Preliminary Results From a Phase I/II Clinical Treatment TrialAkosua A Nti, Leona W Serrano, Harpal S Sandhu, et al.
Clinical Immunology (Orlando, Fla.)|April 2, 2020
Prolonged intraocular residence and retinal tissue distribution of a fourth-generation compstatin-based C3 inhibitor in non-human primatesSarah Hughes, Justin Gumas, Rebecca Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2022
BAMM (BRAF Autophagy and MEK Inhibition in Melanoma): A Phase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine in Advanced BRAFV600-mutant MelanomaJanice M Mehnert, Tara C Mitchell, Alexander C Huang, et al.
Pageof 6